Nadezhda Vasilyeva: Shifting the Boundaries of Acute Ischemic Stroke Management
Nadezhda Vasilyeva, Neurologist, shared a post on LinkedIn:
“The boundaries of acute ischemic stroke management are shifting: the 2026 AHA/ASA guidance allows tenecteplase 0.25 mg/kg as an alternative to alteplase within 4.5 hours or less; concurrently, trials (e.g. HOPE) are investigating selective thrombolysis expansion to 4.5-24 hours using perfusion-based selection.
Antithrombotic management after reperfusion remains a trade-off: ATIS‑NVAF data showed increased bleeding without clear clinical benefit when combining anticoagulants and antiplatelets.
The emergence of Factor XIa inhibitors (e.g. asundexian; Phase III OCEANIC‑STROKE) shows reduced recurrence with an acceptable bleeding profile – potentially addressing a key neuro-safety dilemma.
As a clinician with 5+ years in neurology, I translate this bedside experience into rigorous ICH‑GCP safety monitoring.
Colleagues in research teams – how are you adapting monitoring systems for extended thrombolysis windows and new antithrombotic combinations?”
Stay updated with Hemostasis Today.
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA
-
Oct 19, 2026, 17:44Paul Riley: Moderating a Webinar on Anticoagulation Monitoring
-
Oct 19, 2026, 16:36Christopher Pittman: Blood Clot Prevention Cannot End at Hospital Discharge
-
Oct 19, 2026, 16:13Javier M. Floren: When Immune Cells Move With Their Environment